연구성과로 돌아가기
2023 연구성과별 연구자 정보 (1809 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Oh, Do-Youn | Oh, DY | 10 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Costin, Dan | Costin, D | 11 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Pippas, Andrew William | Pippas, AW | 12 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Chen, Jen-Shi | Chen, JS | 13 | GLV-3349-2022 | Chen, Jen-Shi | |||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Chaney, Marya F. | Chaney, MF | 14 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Koustenis, Andrew | Koustenis, A | 15 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Youssoufian, Hagop | Youssoufian, H | 16 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Makris, Lukas | Makris, L | 17 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Culm, Kerry | Culm, K | 18 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Mockbee, Colleen M. | Mockbee, CM | 19 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Chau, Ian | Chau, I | 20 | ABC-2023-2020 | Chau, Ian | 0000-0003-0286-8703 | Chau, Ian | |||
| Phase-controllable topochemical polymerization of liquid crystalline epoxy according to spacer length | Ku, Kyosun | Ku, K | 1 | Kyungpook Natl Univ, Adv Inst Water Ind, Daegu 41566, South Korea | 0009-0002-9159-7270 | Ku, Kyosun | yeo@knu.ac.kr; | |||
| Phase-controllable topochemical polymerization of liquid crystalline epoxy according to spacer length | Yeo, Hyeonuk | Yeo, H | 2 | 교신저자 | Kyungpook Natl Univ, Dept Chem Educ, Daegu 41566, South Korea | G-7890-2017 | yeo, hyeonuk | 0000-0003-2629-4353 | yeo, hyeonuk | yeo@knu.ac.kr; |
| Phase-controllable topochemical polymerization of liquid crystalline epoxy according to spacer length | Yeo, Hyeonuk | Yeo, H | 2 | 교신저자 | Kyungpook Natl Univ, Dept Pharm, Daegu 41566, South Korea | G-7890-2017 | yeo, hyeonuk | 0000-0003-2629-4353 | yeo, hyeonuk | yeo@knu.ac.kr; |
| Phase-field analysis of the effects of particle size, diffusivities, and mechanical properties on the cracking of silicon nanoparticle | Choi, Junhyeok | Choi, J | 1 | Kyungpook Natl Univ, Sch Mech Engn, Daegu 702701, South Korea | 0009-0008-8262-0030 | Choi, Junhyeok | sykim.knu@gmail.com; |
페이지 이동: